Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Pemphigus
NCT06663943Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cm313 in pemphigus vulgaris (PV). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cm313
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT06663943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663943.